Molecular Partners AG (MOLN)
undefined
undefined%
At close: undefined
5.43
0.37%
After-hours Dec 13, 2024, 03:58 PM EST

Company Description

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins.

Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.

The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers.

It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life.

Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators.

The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG
Molecular Partners AG logo
Country CH
IPO Date Jun 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 167
CEO Dr. Patrick Amstutz Ph.D.

Contact Details

Address:
Wagistrasse 14
Schlieren,
CH
Website https://www.molecularpartners.com

Stock Details

Ticker Symbol MOLN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001745114
CUSIP Number 60853G106
ISIN Number US60853G1067
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Dr. Patrick Amstutz Ph.D. Co-Founder, Chief Executive Officer, Member of Management Board & Director
Alexander Zurcher Chief Operating Officer & Member of Management Board
Anne Goubier D.V.M., Ph.D. Senior Vice President of Research & Early Development
Daniel Steiner Ph.D. Senior Vice President of Research & Technology
Dr. Michael Tobias Stumpp Ph.D. Co-Founder, Executive Vice President of Projects & Member of Management Board
Dr. Pamela A. Trail Ph.D. Strategic Consultant
Michael Pitzner General Counsel, Compliance Officer, Senior Vice President Legal & Business Development
Renate Gloggner Executive Vice President of People & Community and Member of Management Board
Robert Hendriks Senior Vice President of Finance
Seth D. Lewis Senior Vice President of Investor Relations, Communications & Strategy

Latest SEC Filings

Date Type Title
Oct 31, 2024 6-K Filing
Oct 29, 2024 SC 13D/A [Amend] Filing
Oct 28, 2024 6-K Filing
Oct 25, 2024 424B5 Filing
Oct 22, 2024 6-K Filing
Aug 26, 2024 6-K Filing
Jun 26, 2024 S-8 Filing
Jun 14, 2024 6-K Filing
Jun 11, 2024 6-K Filing
Jun 03, 2024 6-K Filing